<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224509</url>
  </required_header>
  <id_info>
    <org_study_id>EP3 receptors</org_study_id>
    <nct_id>NCT01224509</nct_id>
  </id_info>
  <brief_title>The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors</brief_title>
  <acronym>EP3</acronym>
  <official_title>Cervical Prostaglandin EP3 Receptor mRNA Expression 48 Hours After Administration of Mifepristone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of mifepristone on the expression of
      three cervical EP3 receptor isoforms (EP3-2, EP3-3 and EP3-6) in pregnant women ≤63 days
      gestational age.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Longer than expected recruitment period.
  </why_stopped>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of expression of EP3 receptor mRNA levels in cervical tissue after the administration of mifepristone</measure>
    <time_frame>48 hours after the administration of mifepristone</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The degree of cervical dilation after the administration of mifepristone</measure>
    <time_frame>48 hours after the administration of mifepristone</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Cervical Prostaglandin EP3 Receptors</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity</description>
    <arm_group_label>Mifepristone</arm_group_label>
    <other_name>mifeprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-treatment</intervention_name>
    <description>Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity</description>
    <arm_group_label>Non-treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  good general health

          -  ≥18 years old

          -  seeking termination of a viable intrauterine pregnancy of ≤63 days, without any
             evidence of a threatened or spontaneous abortion

        Exclusion Criteria:

          -  medical problems

          -  confirmed or suspected ectopic pregnancy

          -  having taken medications in the seven days prior to enrollment that would affect PG
             synthesis or metabolism of mifepristone
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Soleil Wagner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John K Jain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's and Children's Hospital, Reproductive Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>October 19, 2010</last_update_submitted>
  <last_update_submitted_qc>October 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Marie-Soleil Wagner, MD</name_title>
    <organization>University of Montreal</organization>
  </responsible_party>
  <keyword>Cervix</keyword>
  <keyword>EP3 receptors</keyword>
  <keyword>Mifepristone</keyword>
  <keyword>Prostaglandin</keyword>
  <keyword>Receptors</keyword>
  <keyword>Steroids</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

